- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT07157007
- Original Trial
Early-stage Trial to Determine a Safe and Effective Dose for Ratutrelvir in Patients With Mild to Moderate COVID-19
A Multicenter, Open-Label, Randomized Phase 2a Study to Evaluate Safety and Efficacy of Ratutrelvir and Standard of Care in Non-hospitalized Symptomatic Adult Participants With Mild to Moderate COVID-19
This is an Early-stage Clinical Trial to Determine a Safe and Effective Dose for Ratutrelvir in Patients With Mild to Moderate COVID-19. It will also learn about the safety of drug Ratutrelvir. Participants will take a study drug as well as a standard therapy. A descriptive statistics will be used to present the study results.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This is a multicenter, open-label, randomized Phase 2a study to evaluate the safety and efficacy of 83-0060 (Ratutrelvir) and Nirmatrelvir-Ritonavir (Paxlovid) in non-hospitalized symptomatic adult participants with mild to moderate COVID-19.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Tashkent
-
Tashkent, Tashkent, Uzbekistan, 100194
- Research Institute of Virology
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Confirmed SARS-CoV-2 infection for 120 h prior to randomization.
- Initial onset of signs/symptoms attributable to COVID-19 within 5 days prior to randomization.
- At least one of the symptoms attributable to COVID-19 present within 24 hours prior to the Day 1 with the severity score of 1 or higher according to the following scoring system for the assessment of severity of:
Exclusion Criteria:
Medical Conditions:
-
History, current need for hospitalization or anticipated need for hospitalization for the medical treatment of COVID-19.
-
Urgent or expected need for nasal high-flow oxygen therapy or positive pressure ventilation, invasive mechanical ventilation or ECMO.
-
Known medical history of active liver disease .
-
Receiving dialysis or history of moderate to severe renal impairment.
-
Compromised immune system.
-
Acute episode of chronic respiratory diseases, including bronchial asthma, chronic obstructive pulmonary disease within 30 days before screening.
-
Suspected or confirmed concurrent active systemic infection..
Prior/Concomitant Therapy:
-
Has received or is expected to receive any dose of a SARS-CoV-2 vaccine within 4 months of screening and during the participation in the study.
-
Concomitant use of any medications or substances that are strong inducers of CYP3A4
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Ratutrelvir (83-0060) non-randomised
|
83-0060, a covalent inhibitor of the SARS-CoV-2 main protease (Mpro; 3CL) |
|
Experimental: Ratutrelvir (83-0060)
|
83-0060, a covalent inhibitor of the SARS-CoV-2 main protease (Mpro; 3CL) |
|
Active Comparator: Paxlovid
Standard of care |
Paxlovid (Nirmatrelvir+ Ritonavir , boosted 3CL-protease inhibitor) |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Safety based on adverse events incidence
Time Frame: 28 days
|
Adverse events incidence will be described using descriptive statistics methods |
28 days
|
|
Safety based on adverse events severity
Time Frame: 28 days
|
Adverse events severity will be assessed by current version of CTCAE |
28 days
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Efficacy based on Time (days) to sustained recovery of all targeted COVID-19 signs/symptoms through Day 28
Time Frame: 28 days
|
28 days
|
|
Efficacy based on Time to sustained recovery of each targeted COVID-19 symptom through Day 28.
Time Frame: 28 days
|
28 days
|
|
PK characteristics of 83-0060 based on Maximum Plasma Concentration (Cmax)
Time Frame: 11 days
|
11 days
|
|
PK characteristics of 83-0060 based on Area under the concentration time curve from 0 to time of last quantifiable concentration (AUClast)
Time Frame: 11 days
|
11 days
|
|
PK characteristics of 83-0060 based on Time to Cmax ( Tmax)
Time Frame: 11 days
|
11 days
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 83-0060-0002
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.